Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ramucirumab · Cyramza, IMC-1121B

Monoclonal antibody · Antagonist of VEGFR2 (vascular endothelial growth factor receptor 2) (KDR) · developed by Eli Lilly And Co

Approved FDA, Apr 2014
LLY Developer
1 Registered trials

What is Ramucirumab?

Ramucirumab is a human monoclonal antibody that specifically binds VEGFR2 and blocks binding of the ligands VEGF-A, VEGF-C and VEGF-D, inhibiting ligand-stimulated VEGFR2 activation and endothelial cell proliferation and migration. It is used in the treatment of gastric or gastro-esophageal junction adenocarcinoma, non-small cell lung cancer, colorectal cancer and hepatocellular carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Cyramza, IMC-1121B, LY3009806
Drug type
Monoclonal antibody
Targets
VEGFR2 (vascular endothelial growth factor receptor 2) (KDR)
Mechanism
Antagonist of VEGFR2 (vascular endothelial growth factor receptor 2) (KDR)
Pathways
angiogenesis, VEGF signaling
Therapy area
Oncology
Developer
Eli Lilly And Co (LLY)
FDA status
Approved as Cyramza (April 21, 2014), BLA125477 · FDA label
UNII
D99YVK4L0X

✅ FDA-approved uses

From the indications section of the FDA label (version of Jun 9, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05002127 Phase 2/3 Gastric Cancer Completed LLY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Gastric AdenocarcinomaGastric CancerGastroesophageal Junction Adenocarcinoma

Other drugs acting on KDR

More from Eli Lilly And Co

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the LLY page.

Follow LLY, the company behind Ramucirumab

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.